Back to top
more

Charles River Laboratories International (CRL)

(Real Time Quote from BATS)

$180.94 USD

180.94
830,357

-0.02 (-0.01%)

Updated Nov 4, 2024 09:34 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 250)

Industry: Medical Services

Better trading starts here.

Zacks News

Is Charles River (CRL) a Solid Growth Stock? 3 Reasons to Think " Yes "

Charles River (CRL) could produce exceptional returns because of its solid growth attributes.

Abbott's (ABT) Diabetes Arm Booms, Neuromodulation Sales Soft

Even though COVID-19 case rates are surging in the United States and other geographies, Abbott is seeing growth in its consumer-facing businesses like nutrition, EPD and diabetes care.

Here's Why You Should Hold on to Tandem Diabetes (TNDM) for Now

Investors are optimistic about Tandem Diabetes' (TNDM) t:slim X2 technology and greater use of Control-IQ technology.

3 Reasons Why Charles River (CRL) Is a Great Growth Stock

Charles River (CRL) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?

Smart Beta ETF report for FBT

Here's Why You Should Retain Charles River (CRL) Stock for Now

Investors are optimistic about Charles River (CRL) on acquisitions of Cognate BioServices and Vigene Biosciences.

Charles River (CRL) Down 3.5% Since Last Earnings Report: Can It Rebound?

Charles River (CRL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Charles River (CRL) Q3 Earnings Beat Estimates, EPS View Up

Charles River (CRL) exited the third quarter of 2021 with better-than-expected earnings on strength in the RMS, DSA and Manufacturing Solutions arms driving the top line.

Charles River Laboratories (CRL) Q3 Earnings Top Estimates

Charles River (CRL) delivered earnings and revenue surprises of 5.06% and -1.39%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Charles River (CRL) to Report Q3 Earnings: What's in the Cards?

Robust demand for research models and the Vigene Biosciences buyout are likely to have contributed to growth for Charles River (CRL).

Charles River Laboratories (CRL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?

Smart Beta ETF report for FBT

Charles River (CRL) to Offer Cryo-EM Capabilities With New Pact

Charles River's (CRL) recent partnership will enable the company to improve drug discovery projects by allowing structure-based design for a greater portfolio of targets.

Here's Why You Should Invest in Charles River (CRL) Now

Investors are optimistic about Charles River (CRL) on solid second-quarter performance and bullish 2021 guidance.

Why Is Charles River (CRL) Up 9.5% Since Last Earnings Report?

Charles River (CRL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Charles River (CRL) at a 52-Week High: What's Driving It?

Charles River (CRL) ended the second quarter on a strong note with solid performance by the RMS, DSA and Manufacturing Support arms driving the top line.

MODV or CRL: Which Is the Better Value Stock Right Now?

MODV vs. CRL: Which Stock Is the Better Value Option?

Charles River (CRL) Q2 Earnings Beat Estimates, 2021 View Up

Robust performance by all three segments drove Charles River's (CRL) revenues in the second quarter.

Charles River Laboratories (CRL) Q2 Earnings and Revenues Surpass Estimates

Charles River (CRL) delivered earnings and revenue surprises of 9.21% and 5.17%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Charles River (CRL) Q2 Earnings to Mirror Broad-Based Demand

Charles River's (CRL) biotech clients are likely to have benefited from a robust funding environment in Q2.

Charles River Laboratories (CRL) Earnings Expected to Grow: Should You Buy?

Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Charles River (CRL) at a 52-Week High: What's Driving It?

Strong performance by the RMS, DSA and Manufacturing segments is driving the top line for Charles River (CRL).

Sweta Killa headshot

10 Top-Ranked Stocks Powering S&P 500 ETF

The S&P 500 has been outperforming this year due to the strength in value and cyclical stocks, which were battered last year in the pandemic.